Glenn Gregory M 4
4 · NOVAVAX INC · Filed Dec 16, 2021
Insider Transaction Report
Form 4
NOVAVAX INCNVAX
Glenn Gregory M
Chief Scientific Officer
Transactions
- Sale
Common Stock
2021-12-15$175.89/sh−67$11,785→ 6,222 total - Sale
Common Stock
2021-12-15$171.47/sh−254$43,553→ 6,765 total - Sale
Common Stock
2021-12-15$174.65/sh−137$23,927→ 6,289 total - Sale
Common Stock
2021-12-15$170.46/sh−213$36,309→ 7,019 total - Sale
Common Stock
2021-12-15$176.83/sh−223$39,432→ 5,999 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-15−662→ 7,944 totalExercise: $46.00Exp: 2028-12-13→ Common Stock (662 underlying) - Exercise/Conversion
Common Stock
2021-12-15$27.60/sh+1,024$28,262→ 6,687 total - Sale
Common Stock
2021-12-15$178.99/sh−103$18,436→ 5,896 total - Sale
Common Stock
2021-12-15$168.82/sh−117$19,752→ 7,232 total - Sale
Common Stock
2021-12-15$173.29/sh−91$15,770→ 6,426 total - Exercise/Conversion
Restricted Stock Units
2021-12-14−3,100→ 6,200 total→ Common Stock (3,100 underlying) - Exercise/Conversion
Common Stock
2021-12-14+3,100→ 7,161 total - Exercise/Conversion
Common Stock
2021-12-15$46.00/sh+662$30,452→ 7,349 total - Sale
Common Stock
2021-12-15$180.62/sh−27$4,877→ 5,663 total - Tax Payment
Common Stock
2021-12-14$168.43/sh−1,498$252,308→ 5,663 total - Sale
Common Stock
2021-12-15$172.38/sh−248$42,750→ 6,517 total - Sale
Common Stock
2021-12-15$179.58/sh−206$36,993→ 5,690 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-15−1,024→ 0 totalExercise: $27.60Exp: 2027-12-15→ Common Stock (1,024 underlying)
Footnotes (16)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
- [F10]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.42 to $177.36, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F11]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.29 to $179.26, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F12]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.31 to $179.89, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F13]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.47 to $180.81, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F14]The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date.
- [F15]Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
- [F16]Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
- [F2]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.61 to $169.27, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F4]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.78 to $170.71, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F5]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.94 to $171.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F6]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.97 to $172.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F7]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.97 to $173.79, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F8]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.03 to $175.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F9]The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.31 to $176.29, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.